PubMed Health⌕ Search

Biomedical subjects

R Saynor

Publications and source records attributed to R Saynor.

14 recordsLinked to original sources
PubMed1994

Effects of a low-dose fish oil concentrate on angina, exercise tolerance time, serum triglycerides, and platelet function.

Fish oils have shown beneficial effects on various parameters in patients with coronary artery disease (CAD). The purpose of this study was to investigate whether the same effects can be demonstrated with a low dose of fish oil concentrate (FOC). Thirty-nine patients were studied and divided into two groups. Twenty were given 10 g fish oil (group A) and 19 were given 10 g placebo Italian olive oil (group B). Weekly anginal attacks (AA), weekly glyceryl trinitrate consumption (GTN), exercise tolerance time (ETT), serum triglycerides (ST), platelet aggregation ratio (PAR), and beta-thromboglobulin were measured at eight and twelve weeks after start of treatment. 1. The number of anginal attacks recorded by both groups decreased by 41% in group A reaching statistical significance (P < 0.05). No change was observed in group B. 2. GTN consumption decreased in group A (P < 0.05) with no significant change in group B (P:ns). 3. ETT increased significantly in group A eight and twelve weeks after start of treatment (20.6% P < 0.01, 22.6% P < 0.01). A smaller but insignificant increase was observed in group B (P: ns). 4. ST decreased significantly in group A by 22% eight weeks after start of treatment (P < 0.01) and to a lesser degree (11%) twelve weeks after start of treatment (P: ns). In group B, ST slightly increased (P: ns). 5. No statistically significant change was observed in either group in regard to PAR and beta-thromboglobulin (P: ns). These observations suggest that dietary supplementation with a low dose of FOC may have beneficial effects on the clinical status of patients with CAD.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1992

Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years.

The present study was designed to assess the effectiveness of the n-3 fatty acids in modifying serum total, low density lipoprotein and high density lipoprotein (HDL) cholesterol, as well as serum triglycerides, over a seven-year period. Changes in plasma fibrinogen were recorded and long term safety assessed. A total of 365 subjects with ischemic heart disease (IHD), hyperlipidemia or a strong family history of IHD had their diet supplemented with MaxEPA (Seven Seas Ltd., Hull, England) fish oil containing 18-19% eicosapentaenoic acid. Venous blood samples were taken at regular intervals for lipid and fibrinogen assays and routine clinical chemistry and hematological profiling. Current medication was recorded and no further dietary modification was attempted. Triglyceride and fibrinogen were significantly reduced, whereas a significant reduction in total cholesterol occurred only in the subjects with a pre-oil level greater than 6.5 mmol/L. HDL cholesterol significantly increased over the study period. Clinical chemistry and hematological profiles were not adversely affected, and platelet count did not change significantly. The type of lipid changes observed were those usually considered antiatherogenic. Reducing fibrinogen may result in beneficial changes in the pathological processes leading to thrombotic occlusion. The consumption of MaxEPA by our patients over a seven-year period did not indicate any adverse effects.

Adolescent↗
PubMed1988

Triglyceride lowering effect of MaxEPA fish lipid concentrate: a multicentre placebo controlled double blind study.

A multicentre, double blind, randomised between-group study comparing the triglyceride lowering effect of MaxEPA, a natural marine oil, and a placebo control is described. Eighty-six patients with hypertriglyceridaemia (fasting serum triglyceride greater than or equal to 2 mmol/l) were studied for three months. There were no significant differences between the groups (48 active, 38 control) in respect of age, sex, height or weight, smoking habits or alcohol consumption. After one month triglyceride levels were reduced significantly from baseline in the treatment group and there was also a highly significant difference between the groups in favour of the marine oil. There was no significant change in serum total cholesterol in either group but there were fluctuations in high density lipoprotein (HDL) in both groups. Minor gastrointestinal side effects were reported by patients in both groups. Standard haematological and biochemical tests were done and there were no significant changes from baseline.

Adolescent↗
PubMed1986

Chalk in the prime.

After observations of cloudiness in the perfusion circuit at open intracardiac operations, laboratory experiments showed a precipitate in a Hartmann's solution (compound sodium lactate solution, Ringer-lactate) and sodium bicarbonate based priming fluid used for cardiopulmonary bypass. The precipitate was found to consist of calcium carbonate crystals. The crystals were not dissolved by adding plasma proteins, nor were they sufficiently cleared from the extracorporeal circuit by a 40 microns filter in the arterial line. The crystals may embolise in microvascular beds and thus be a cause of postoperative morbidity. The practice of adding sodium bicarbonate to the pump prime may be unnecessary.

Bicarbonates↗
PubMed1986

Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients.

Haemodialysis patients have an exceptionally high incidence of death from cardiovascular causes, related in part to abnormalities of lipids and platelets. Eskimos, however, have a low incidence of myocardial infarction and have a high dietary intake of fish, rich in omega-3 polyunsaturated fatty acids. We have, therefore, studied the effect of a fish oil MaxEPA, containing 3.6 g of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid on lipids and platelet function in haemodialysis patients. Following 8 weeks of therapy there was a 35% fall in triglycerides, a 10% rise of high-density lipoprotein (HDL) cholesterol, a 36% rise of HDL2 cholesterol fraction and a 54% rise of the HDL2:HDL3 cholesterol ratio. The platelet aggregation to adenosine diphosphate and collagen was significantly reduced. The activated whole-blood clotting time was prolonged from 141 to 153 s, and 69% of patients showed a reduction of factor VIII related antigen which is usually elevated in haemodialysis patients and is thought to be a marker of endothelial damage. The blood pressure fell from 147/82 to 124/74. We have thus shown that a dietary supplement of eicosapentaenoic acid produces potentially beneficial effects on lipids, platelets, and blood pressure and may help to protect against atheroma and thus cardiovascular mortality in high-risk haemodialysis patients.

Adolescent↗
PubMed1984

The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina.

The effect of a fish lipid concentrate rich in eicosapentaenoic acid was studied in 107 subjects for periods up to 2 years. Ninety-two had heart disease or hyper-lipidaemia and 15 had no history of heart disease. Serum triglyceride levels were rapidly reduced, cholesterol fell more slowly but high density lipoprotein (HDL) cholesterol was increased. Bleeding time increased significantly and the consumption of glyceryl trinitrate (GTN) tablets decreased together with a reduction in anginal attacks. The data are consistent with a reduction in hepatic triglyceride synthesis rather than an increased rate of triglyceride clearance. Total and HDL cholesterol changes are suggestive of an enhanced removal of cholesterol from the tissues. Increased bleeding time and changes in GTN consumption are consistent with decreased platelet aggregation.

Adult↗
PubMed1982

Effect of fish oil on platelet kinetics in patients with ischaemic heart disease.

The effect of taking fish oil rich in eicosapentaenoic acid on platelet kinetics was studied in 13 patients with ischaemic heart disease. No other change in diet, medication, or smoking habits was permitted. The fish oil provided 3.5 g of eicosapentaenoic acid a day. After 5 weeks the fish oil caused a 10% lengthening in platelet survival time, a 15% fall in platelet count, a 75% fall in plasma levels of platelet factor 4, and a 30% fall in plasma-beta-thromboglobulin. These findings suggest that a diet rich in omega-3 polyunsaturated fatty acids, such as eicosapentaenoic acid, will reduce platelet/vessel-wall interaction and may reduce the risk of ischaemic heart disease. Long-term studies to explore the toxicity and alleged protective effects of fish oil are justified.

Adult↗